374 related articles for article (PubMed ID: 28746182)
1. Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
Pan M; Li W; Yang J; Li Z; Zhao J; Xiao Y; Xing Y; Zhang X; Ju W
Medicine (Baltimore); 2017 Jul; 96(30):e7405. PubMed ID: 28746182
[TBL] [Abstract][Full Text] [Related]
2. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
4. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment.
Sanna V; Siddiqui IA; Sechi M; Mukhtar H
Mol Pharm; 2013 Oct; 10(10):3871-81. PubMed ID: 23968375
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
8. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
Eivazi N; Rahmani R; Paknejad M
Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
10. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy.
Chen Z; Tai Z; Gu F; Hu C; Zhu Q; Gao S
Eur J Pharm Biopharm; 2016 Oct; 107():130-41. PubMed ID: 27393562
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
[TBL] [Abstract][Full Text] [Related]
15. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
16. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
[TBL] [Abstract][Full Text] [Related]
18. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Aravind A; Jeyamohan P; Nair R; Veeranarayanan S; Nagaoka Y; Yoshida Y; Maekawa T; Kumar DS
Biotechnol Bioeng; 2012 Nov; 109(11):2920-31. PubMed ID: 22615073
[TBL] [Abstract][Full Text] [Related]
19. PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
Owiti AO; Pal D; Mitra A
AAPS PharmSciTech; 2018 Nov; 19(8):3534-3549. PubMed ID: 30151731
[TBL] [Abstract][Full Text] [Related]
20. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
